Overview These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer are the work of the members of the NCCN Breast Cancer Panel. Categories of evidence and consensus were assessed and are noted in the algorithms and text. Although not explicitly stated at every decision point of the NCCN Guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer. The full breast cancer guidelines are not printed in this issue of JNCCN, but can be accessed online at www.NCCN.org. The American Cancer Society estimated that 209,060 new cases of invasive breast cancer were diagnosed and 40,230 people died of breast cancer in the United States in 2010.1 In addition, approximately 54,010 women were diagnosed with carcinoma in situ of the breast during the same year. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The incidence of breast cancer has increased steadily in the United States over the past few decades, but breast cancer mortality seems to be declining,1,2 suggesting a benefit from early detection and more effective treatment. The cause of most breast cancer cases is unknown. However, numerous risk factors for the disease have been established, including female gender, increasing patient age, family history of breast cancer at a young age, early menarche, late menopause, older age at first live birth, prolonged hormone replacement therapy, previous exposure to therapeutic chest...
  • 1.

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2.

    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 3.

    Gail MH, Costantino JP, Bryant J. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:18291846.

    • Search Google Scholar
    • Export Citation
  • 4.

    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146151.

  • 5.

    White J, Morrow M, Moughan J. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893904.

    • Search Google Scholar
    • Export Citation
  • 6.

    Wilkinson NW, Shahryarinejad A, Winston JS. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:3843.

    • Search Google Scholar
    • Export Citation
  • 7.

    Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155168.

    • Search Google Scholar
    • Export Citation
  • 8.

    Rhodes A, Jasani B, Barnes DM. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125130.

    • Search Google Scholar
    • Export Citation
  • 9.

    Rudiger T, Hofler H, Kreipe HH. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873882.

    • Search Google Scholar
    • Export Citation
  • 10.

    Allred DC, Carlson RW, Berry DA. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7(Suppl 6):121.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hammond MEH, Hayes DF, Dowsett M. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:27842795.

    • Search Google Scholar
    • Export Citation
  • 12.

    Wang S, Saboorian MH, Frenkel E. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374381.

    • Search Google Scholar
    • Export Citation
  • 13.

    DAKO HercepTest [package insert] Carpinteria, Calif: DAKO Corp; 2004.

  • 14.

    Pathway HER2 [package insert]. Tucson, Ariz: Ventana Medical Systems, Inc.; 2004.

  • 15.

    INFORM HER2/neu gene detection system [package insert]. Tucson, Ariz: Ventana Medical Systems, Inc.; 2001.

  • 16.

    Pathvysion HER2/neu method [package insert]. Downers Grove, Ill. Vysis, Inc.; 2001.

  • 17.

    HER2 FISH pharmDx Kit [package insert]. Dako Denmark A/S, Glostrup, Denmark; 2005.

  • 18.

    SPOT-Light HER2 CISH kit [package insert], Camarillo, CA, Invitrogen Corp.; 2008.

  • 19.

    Dybdal N, Leiberman G, Anderson S. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:311.

    • Search Google Scholar
    • Export Citation
  • 20.

    Paik S, Bryant J, Tan-Chiu E. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852854.

    • Search Google Scholar
    • Export Citation
  • 21.

    Paik S, Tan-Chiu E, Bryant J. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin [abstract]. Breast Cancer Res Treat 2002;76(Suppl):Abstract S31.

    • Search Google Scholar
    • Export Citation
  • 22.

    Perez EA, Suman VJ, Davidson NE. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:30323038.

    • Search Google Scholar
    • Export Citation
  • 23.

    Tubbs RR, Pettay JD, Roche PC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:27142721.

    • Search Google Scholar
    • Export Citation
  • 24.

    Press MF, Sauter G, Bernstein L. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:65986607.

    • Search Google Scholar
    • Export Citation
  • 25.

    Carlson RW, Moench SJ, Hammond ME. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):122.

    • Search Google Scholar
    • Export Citation
  • 26.

    Wolff AC, Hammond ME, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118145.

    • Search Google Scholar
    • Export Citation
  • 27.

    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678687.

  • 28.

    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235237.

  • 29.

    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:16011602.

  • 30.

    Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159169.

  • 31.

    Houssami N, Ciatto S, Macaskill P. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:32483258.

    • Search Google Scholar
    • Export Citation
  • 32.

    Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009;7:193201.

    • Search Google Scholar
    • Export Citation
  • 33.

    Fischer U, Zachariae O, Baum F. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:17251731.

    • Search Google Scholar
    • Export Citation
  • 34.

    Solin LJ, Orel SG, Hwang WT. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386391.

    • Search Google Scholar
    • Export Citation
  • 35.

    Baseline Staging Tests in Primary Breast Cancer: Practice Guideline Report # 1-14: Members of the Breast Cancer Disease Site Group. 2003. Available at: http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc1-14f.pdf. Accessed December 20, 2010.

    • Search Google Scholar
    • Export Citation
  • 36.

    Puglisi F, Follador A, Minisini AM. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263266.

    • Search Google Scholar
    • Export Citation
  • 37.

    Carr CE, Conant EF, Rosen MA. The impact of FDG PET in the staging of breast cancer [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 530.

  • 38.

    Khan QJ, O'Dea AP, Dusing R. Integrated FDG-PET/CT for initial staging of breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 558.

    • Search Google Scholar
    • Export Citation
  • 39.

    Kumar R, Chauhan A, Zhuang H. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267274.

    • Search Google Scholar
    • Export Citation
  • 40.

    Podoloff DA, Advani RH, Allred C. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):122.

    • Search Google Scholar
    • Export Citation
  • 41.

    Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27(Suppl 1):S215229.

  • 42.

    Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277285.

    • Search Google Scholar
    • Export Citation
  • 43.

    Kranick JA, Schaefer C, Rowell S. Is pregnancy after breast cancer safe? Breast J 2010;16:404411.

  • 44.

    Cruz MR, Prestes JC, Gimenes DL, Fanelli MF. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. Fertil Steril 2010;94:138143.

    • Search Google Scholar
    • Export Citation
  • 45.

    Dunn L, Fox KR. Techniques for fertility preservation in patients with breast cancer. Curr Opin Obstet Gynecol 2009;21:6873.

  • 46.

    Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486492.

  • 47.

    Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:6473.

  • 48.

    Sukumvanich P, Case LD, Van Zee K. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:31023111.

    • Search Google Scholar
    • Export Citation
  • 49.

    Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:15581564.

    • Search Google Scholar
    • Export Citation
  • 50.

    Clarke M, Collins R, Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:20872106.

    • Search Google Scholar
    • Export Citation
  • 51.

    Fisher B, Anderson S, Bryant J. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:12331241.

    • Search Google Scholar
    • Export Citation
  • 52.

    Veronesi U, Cascinelli N, Mariani L. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:12271232.

    • Search Google Scholar
    • Export Citation
  • 53.

    Pignol J, Olivotto I, Rakovitch E. Plenary 1: phase III randomized study of intensity modulated radiation therapy versus standard wedging technique for adjuvant breast radiotherapy [abstract]. Int J Radiat Oncol Biol Phys 2006;66(Suppl 1):S1.

    • Search Google Scholar
    • Export Citation
  • 54.

    Whelan T, MacKenzie R, Julian J. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:11431150.

    • Search Google Scholar
    • Export Citation
  • 55.

    Antonini N, Jones H, Horiot JC. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007;82:265271.

    • Search Google Scholar
    • Export Citation
  • 56.

    Bartelink H, Horiot JC, Poortmans P. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:13781387.

    • Search Google Scholar
    • Export Citation
  • 57.

    Jones H, Antonini N, Colette L. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC Boost-No Boost trial [abstract]. Int J Radiat Oncol Biol Phys 2007;69(Suppl 1):Plenary 4, S2S3.

    • Search Google Scholar
    • Export Citation
  • 58.

    Fourquet A, Campana F, Zafrani B. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719725.

    • Search Google Scholar
    • Export Citation
  • 59.

    Komoike Y, Akiyama F, Iino Y. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:3541.

    • Search Google Scholar
    • Export Citation
  • 60.

    Pierce LJ, Griffith KA, Buys S. Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 536.

    • Search Google Scholar
    • Export Citation
  • 61.

    Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:5157.

    • Search Google Scholar
    • Export Citation
  • 62.

    Golshan M, Miron A, Nixon AJ. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:5862.

    • Search Google Scholar
    • Export Citation
  • 63.

    Kroman N, Holtveg H, Wohlfahrt J. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688693.

    • Search Google Scholar
    • Export Citation
  • 64.

    McCormick B. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301307.

    • Search Google Scholar
    • Export Citation
  • 65.

    Smith BD, Arthur DW, Buchholz TA. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74:9871001.

    • Search Google Scholar
    • Export Citation
  • 66.

    Shaitelman SF, Vicini FA, Beitsch P. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer 2010;116:46774685.

    • Search Google Scholar
    • Export Citation
  • 67.

    Vicini F, Arthur D, Wazer D. Limitations of the American Society of Therapeutic Radiology and Oncology consensus panel guidelines on the use of accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2010; in press.

    • Search Google Scholar
    • Export Citation
  • 68.

    Recht A. Contralateral prophylactic mastectomy: caveat emptor. J Clin Oncol 2009;27:13471349.

  • 69.

    Bedrosian I, Hu C, Chang GH. Contralateral prophylactic mastectomy and survival [abstract]. Presented at the 2008 ASCO Breast Cancer Symposium; September 5–7, 2008; Washington, DC. Abstract 2.

    • Search Google Scholar
    • Export Citation
  • 70.

    Hughes KS, Schnaper LA, Berry D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971977.

    • Search Google Scholar
    • Export Citation
  • 71.

    Hughes KS, Schnaper LA, Cirrincione C. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 507.

    • Search Google Scholar
    • Export Citation
  • 72.

    Fyles AW, McCready DR, Manchul LA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963970.

    • Search Google Scholar
    • Export Citation
  • 73.

    Bellon JR, Come SE, Gelman RS. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:19341940.

    • Search Google Scholar
    • Export Citation
  • 74.

    Recht A, Come SE, Henderson IC. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:13561361.

    • Search Google Scholar
    • Export Citation
  • 75.

    Bass SS, Lyman GH, McCann CR. Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288295.

  • 76.

    Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8:67S70S.

  • 77.

    Cox CE, Nguyen K, Gray RJ. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513519.

  • 78.

    Krag D, Weaver D, Ashikaga T. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941946.

  • 79.

    Krag DN, Anderson SJ, Julian TB. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract LBA505.

    • Search Google Scholar
    • Export Citation
  • 80.

    Kuehn T, Vogl FD, Helms G. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252259.

    • Search Google Scholar
    • Export Citation
  • 81.

    Lyman GH, Giuliano AE, Somerfield MR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:77037720.

    • Search Google Scholar
    • Export Citation
  • 82.

    McMasters KM, Giuliano AE, Ross MI. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998;339:990995.

    • Search Google Scholar
    • Export Citation
  • 83.

    O'Hea BJ, Hill AD, El-Shirbiny AM. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423427.

    • Search Google Scholar
    • Export Citation
  • 84.

    Veronesi U, Paganelli G, Viale G. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546553.

    • Search Google Scholar
    • Export Citation
  • 85.

    Mansel RE, Fallowfield L, Kissin M. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599609.

    • Search Google Scholar
    • Export Citation
  • 86.

    Cox CE, Salud CJ, Cantor A. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593600.

    • Search Google Scholar
    • Export Citation
  • 87.

    Dupont E, Cox C, Shivers S. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:9296.

  • 88.

    Cote R, Giuliano AE, Hawes D. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract CRA504.

    • Search Google Scholar
    • Export Citation
  • 89.

    Degnim AC, Reynolds C, Pantvaidya G. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005;190:543550.

    • Search Google Scholar
    • Export Citation
  • 90.

    Houvenaeghel G, Nos C, Giard S. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009;35:690695.

    • Search Google Scholar
    • Export Citation
  • 91.

    Katz A, Smith BL, Golshan M. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008;26:20932098.

    • Search Google Scholar
    • Export Citation
  • 92.

    Kohrt HE, Olshen RA, Bermas HR. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008;8:6666.

    • Search Google Scholar
    • Export Citation
  • 93.

    Scow JS, Degnim AC, Hoskin TL. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer 2009;115:40644070.

    • Search Google Scholar
    • Export Citation
  • 94.

    van la Parra RF, Ernst MF, Bevilacqua JLB. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol 2009;16:11281135.

    • Search Google Scholar
    • Export Citation
  • 95.

    Werkoff G, Lambaudie E, Fondrinier E. Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol 2009;27:57075712.

    • Search Google Scholar
    • Export Citation
  • 96.

    Giuliano AE, McCall L, Beitsch P. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426432.

    • Search Google Scholar
    • Export Citation
  • 97.

    Giuliano AE, McCall LM, Beitsch PD. ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract CRA506.

    • Search Google Scholar
    • Export Citation
  • 98.

    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:14151418.

    • Search Google Scholar
    • Export Citation
  • 99.

    Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:24962501.

    • Search Google Scholar
    • Export Citation
  • 100.

    Fisher B, Redmond C, Fisher ER. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674681.

    • Search Google Scholar
    • Export Citation
  • 101.

    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer 2008;114:8993.

    • Search Google Scholar
    • Export Citation
  • 102.

    Classe JM, Bordes V, Campion L. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726732.

    • Search Google Scholar
    • Export Citation
  • 103.

    Hunt KK, Yi M, Mittendorf EA. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009; in press.

    • Search Google Scholar
    • Export Citation
  • 104.

    Fisher B, Bryant J, Wolmark N. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:26722685.

    • Search Google Scholar
    • Export Citation
  • 105.

    Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:20192027.

    • Search Google Scholar
    • Export Citation
  • 106.

    Hudis C, Modi S. Preoperative chemotherapy for breast cancer: miracle or mirage? JAMA 2007;298:26652667.

  • 107.

    Buzdar AU, Ibrahim NK, Francis D. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:36763685.

    • Search Google Scholar
    • Export Citation
  • 108.

    Buzdar AU, Valero V, Ibrahim NK. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228233.

    • Search Google Scholar
    • Export Citation
  • 109.

    Ellis MJ, Coop A, Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:38083816.

    • Search Google Scholar
    • Export Citation
  • 110.

    Smith IE, Dowsett M, Ebbs SR. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:51085116.

    • Search Google Scholar
    • Export Citation
  • 111.

    Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996997.

  • 112.

    Overgaard M, Hansen PS, Overgaard J. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949955.

    • Search Google Scholar
    • Export Citation
  • 113.

    Overgaard M, Jensen MB, Overgaard J. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:16411648.

    • Search Google Scholar
    • Export Citation
  • 114.

    Ragaz J, Olivotto IA, Spinelli JJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116126.

    • Search Google Scholar
    • Export Citation
  • 115.

    Recht A, Edge SB, Solin LJ. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:15391569.

    • Search Google Scholar
    • Export Citation
  • 116.

    Huang EH, Tucker SL, Strom EA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:46914699.

    • Search Google Scholar
    • Export Citation
  • 117.

    McGuire SE, Gonzalez-Angulo AM, Huang EH. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:10041009.

    • Search Google Scholar
    • Export Citation
  • 118.

    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247253.

    • Search Google Scholar
    • Export Citation
  • 119.

    Nielsen HM, Overgaard M, Grau C. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:22682275.

    • Search Google Scholar
    • Export Citation
  • 120.

    Ahmed S, Snelling A, Bains M, Whitworth IH. Breast reconstruction. BMJ 2005;330:943948.

  • 121.

    Toth BA, Forley BG, Calabria R. Retrospective study of the skin-sparing mastectomy in breast reconstruction. Plast Reconstr Surg 1999;104:7784.

    • Search Google Scholar
    • Export Citation
  • 122.

    Carlson GW, Styblo TM, Lyles RH. The use of skin sparing mastectomy in the treatment of breast cancer: the Emory experience. Surg Oncol 2003;12:265269.

    • Search Google Scholar
    • Export Citation
  • 123.

    Downes KJ, Glatt BS, Kanchwala SK. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer 2005;103:906913.

    • Search Google Scholar
    • Export Citation
  • 124.

    Foster RD, Esserman LJ, Anthony JP. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol 2002;9:462466.

    • Search Google Scholar
    • Export Citation
  • 125.

    Medina-Franco H, Vasconez LO, Fix RJ. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002;235:814819.

    • Search Google Scholar
    • Export Citation
  • 126.

    Newman LA, Kuerer HM, Hunt KK. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 1998;5:620626.

    • Search Google Scholar
    • Export Citation
  • 127.

    Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg 2009;124:395408.

    • Search Google Scholar
    • Export Citation
  • 128.

    Tran NV, Chang DW, Gupta A. Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 2001;108:7882.

    • Search Google Scholar
    • Export Citation
  • 129.

    Mehta VK, Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J 2004;10:118122.

  • 130.

    Garcia-Etienne CA, Cody Iii HS, Disa JJ. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J 2009;15:440449.

    • Search Google Scholar
    • Export Citation
  • 131.

    Petit JY, Veronesi U, Orecchia R. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat 2009;117:333338.

    • Search Google Scholar
    • Export Citation
  • 132.

    Yueh JH, Houlihan MJ, Slavin SA. Nipple-sparing mastectomy: evaluation of patient satisfaction, aesthetic results, and sensation. Ann Plast Surg 2009;62:586590.

    • Search Google Scholar
    • Export Citation
  • 133.

    Chung AP, Sacchini V. Nipple-sparing mastectomy: where are we now? Surg Oncol 2008;17:261266.

  • 134.

    Gerber B, Krause A, Dieterich M. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009;249:461468.

    • Search Google Scholar
    • Export Citation
  • 135.

    Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. Lancet Oncol 2005;6:145157.

    • Search Google Scholar
    • Export Citation
  • 136.

    Huemer GM, Schrenk P, Moser F. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390398.

    • Search Google Scholar
    • Export Citation
  • 137.

    Malycha PL, Gough IR, Margaritoni M. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg 2008;32:25702577.

    • Search Google Scholar
    • Export Citation
  • 138.

    Kaur N, Petit JY, Rietjens M. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539545.

    • Search Google Scholar
    • Export Citation
  • 139.

    Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972979.

  • 140.

    Ravdin PM, Siminoff LA, Davis GJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980991.

    • Search Google Scholar
    • Export Citation
  • 141.

    Muss HB, Berry DA, Cirrincione CT. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:20552065.

  • 142.

    Olivotto IA, Bajdik CD, Ravdin PM. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:27162725.

    • Search Google Scholar
    • Export Citation
  • 143.

    Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189196.

    • Search Google Scholar
    • Export Citation
  • 144.

    Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):2328.

  • 145.

    Paik S, Bryant J, Park C. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:13611370.

    • Search Google Scholar
    • Export Citation
  • 146.

    Paik S, Bryant J, Tan-Chiu E. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-15. J Natl Cancer Inst 2000;92:19911998.

    • Search Google Scholar
    • Export Citation
  • 147.

    Piccart MJ, Di Leo A, Hamilton A. HER2. a `predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:17551761.

    • Search Google Scholar
    • Export Citation
  • 148.

    Pritchard KI, Shepherd LE, O'Malley FP. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:21032111.

  • 149.

    Thor AD, Berry DA, Budman DR. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:13461360.

    • Search Google Scholar
    • Export Citation
  • 150.

    Dressler LG, Berry DA, Broadwater G. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:42874297.

    • Search Google Scholar
    • Export Citation
  • 151.

    Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 152.

    Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 153.

    Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 154.

    Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. [abstract]. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 52.

    • Search Google Scholar
    • Export Citation
  • 155.

    Cobleigh MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:26392648.

    • Search Google Scholar
    • Export Citation
  • 156.

    Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 157.

    Vogel CL, Cobleigh MA, Tripathy D. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719726.

    • Search Google Scholar
    • Export Citation
  • 158.

    Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291300.

    • Search Google Scholar
    • Export Citation
  • 159.

    Perou CM, Jeffrey SS, van de Rijn M. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:92129217.

    • Search Google Scholar
    • Export Citation
  • 160.

    Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:1086910874.

    • Search Google Scholar
    • Export Citation
  • 161.

    Sorlie T, Tibshirani R, Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:84188423.

    • Search Google Scholar
    • Export Citation
  • 162.

    Wang Y, Klijn JG, Zhang Y. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671679.

    • Search Google Scholar
    • Export Citation
  • 163.

    Glas AM, Floore A, Delahaye LJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.

    • Search Google Scholar
    • Export Citation
  • 164.

    van de Vijver MJ, He YD, van't Veer LJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:19992009.

    • Search Google Scholar
    • Export Citation
  • 165.

    van `t Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530536.

  • 166.

    Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:28172826.

    • Search Google Scholar
    • Export Citation
  • 167.

    Paik S, Tang G, Shak S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:37263734.

    • Search Google Scholar
    • Export Citation
  • 168.

    Fan C, Oh DS, Wessels L. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560569.

  • 169.

    Albain KS, Barlow WE, Shak S. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:5565.

    • Search Google Scholar
    • Export Citation
  • 170.

    Swain SM, Wilson JW, Mamounas EP. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516523.

    • Search Google Scholar
    • Export Citation
  • 171.

    Berry DA, Cirrincione C, Henderson IC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:16581667.

    • Search Google Scholar
    • Export Citation
  • 172.

    Albain KS, Barlow WE, Ravdin PM. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:20552063.

    • Search Google Scholar
    • Export Citation
  • 173.

    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 174.

    Arpino G, Green SJ, Allred DC. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 2004;10:56705676.

    • Search Google Scholar
    • Export Citation
  • 175.

    Berry DA, Muss HB, Thor AD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:34713479.

    • Search Google Scholar
    • Export Citation
  • 176.

    De Laurentiis M, Arpino G, Massarelli E. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 177.

    Eppenberger-Castori S, Kueng W, Benz C. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645656.

    • Search Google Scholar
    • Export Citation
  • 178.

    Knoop AS, Bentzen SM, Nielsen MM. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:33763384.

    • Search Google Scholar
    • Export Citation
  • 179.

    Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27:4652.

  • 180.

    Paik S, Shak S, Tang G. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 181.

    Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:6577.

    • Search Google Scholar
    • Export Citation
  • 182.

    Dowsett M, Allred C, Knox J. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:10591065.

    • Search Google Scholar
    • Export Citation
  • 183.

    Coombes RC, Kilburn LS, Snowdon CF. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559570.

    • Search Google Scholar
    • Export Citation
  • 184.

    Kaufmann M, Jonat W, Hilfrich J. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007;25:26642670.

    • Search Google Scholar
    • Export Citation
  • 185.

    Goss PE, Ingle JN, Martino S. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:12621271.

    • Search Google Scholar
    • Export Citation
  • 186.

    Forbes JF, Cuzick J, Buzdar A. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:4553.

    • Search Google Scholar
    • Export Citation
  • 187.

    Thurlimann B, Keshaviah A, Coates AS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 188.

    Baum M, Budzar AU, Cuzick J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 189.

    Howell A, Cuzick J, Baum M. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 190.

    Duffy S, Jackson TL, Lansdown M. The ATAC (`Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545553.

    • Search Google Scholar
    • Export Citation
  • 191.

    Fallowfield L, Cella D, Cuzick J. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:42614271.

    • Search Google Scholar
    • Export Citation
  • 192.

    Eastell R, Adams JE, Coleman RE. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:10511057.

    • Search Google Scholar
    • Export Citation
  • 193.

    Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the `Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001;85:317324.

    • Search Google Scholar
    • Export Citation
  • 194.

    Buzdar AU, Guastalla JP, Nabholtz JM. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006;107:472480.

    • Search Google Scholar
    • Export Citation
  • 195.

    Mouridsen H, Keshaviah A, Coates AS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:57155722.

    • Search Google Scholar
    • Export Citation
  • 196.

    Rabaglio M, Sun Z, Price KN. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;20:1489.

    • Search Google Scholar
    • Export Citation
  • 197.

    Boccardo F, Rubagotti A, Puntoni M. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:51385147.

    • Search Google Scholar
    • Export Citation
  • 198.

    Boccardo F, Rubagotti A, Guglielmini P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):1014.

    • Search Google Scholar
    • Export Citation
  • 199.

    Coombes RC, Hall E, Gibson LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 200.

    Jakesz R, Jonat W, Gnant M. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455462.

    • Search Google Scholar
    • Export Citation
  • 201.

    Jonat W, Gnant M, Boccardo F. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991996.

    • Search Google Scholar
    • Export Citation
  • 202.

    Goss PE, Ingle JN, Martino S. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 203.

    Goss PE, Ingle JN, Pater JL. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:19481955.

    • Search Google Scholar
    • Export Citation
  • 204.

    Perez EA, Josse RG, Pritchard KI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:36293635.

    • Search Google Scholar
    • Export Citation
  • 205.

    Whelan TJ, Goss PE, Ingle JN. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:69316940.

    • Search Google Scholar
    • Export Citation
  • 206.

    Smith IE, Dowsett M, Yap YS. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:24442447.

    • Search Google Scholar
    • Export Citation
  • 207.

    Yu B, Douglas N, Ferin MJ. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010;116:20992105.

    • Search Google Scholar
    • Export Citation
  • 208.

    Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer--the need for vigilance. J Natl Cancer Inst 2006;98:10961097.

  • 209.

    Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930942.

    • Search Google Scholar
    • Export Citation
  • 210.

    Wood WC, Budman DR, Korzun AH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:12531259.

    • Search Google Scholar
    • Export Citation
  • 211.

    Menard S, Valagussa P, Pilotti S. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329335.

    • Search Google Scholar
    • Export Citation
  • 212.

    Muss HB, Thor AD, Berry DA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:12601266.

    • Search Google Scholar
    • Export Citation
  • 213.

    Watanabe T, Kuranami M, Inoue K. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: results of N-SAS-BC02 trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 516.

    • Search Google Scholar
    • Export Citation
  • 214.

    Bang SM, Heo DS, Lee KH. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:25212526.

    • Search Google Scholar
    • Export Citation
  • 215.

    Fisher B, Anderson S, Tan-Chiu E. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931942.

    • Search Google Scholar
    • Export Citation
  • 216.

    Fisher B, Brown AM, Dimitrov NV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:14831496.

    • Search Google Scholar
    • Export Citation
  • 217.

    Fisher B, Anderson S, Wickerham DL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:18581869.

    • Search Google Scholar
    • Export Citation
  • 218.

    Henderson IC, Berry DA, Demetri GD. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976983.

    • Search Google Scholar
    • Export Citation
  • 219.

    Mamounas EP, Bryant J, Lembersky B. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:36863696.

    • Search Google Scholar
    • Export Citation
  • 220.

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 221.

    Levine MN, Pritchard KI, Bramwell VHC. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:51665170.

    • Search Google Scholar
    • Export Citation
  • 222.

    Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602611.

    • Search Google Scholar
    • Export Citation
  • 223.

    Piccart MJ, Di Leo A, Beauduin M. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:31033110.

    • Search Google Scholar
    • Export Citation
  • 224.

    Roche H, Fumoleau P, Spielmann M. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:56645671.

    • Search Google Scholar
    • Export Citation
  • 225.

    Ellis P, Barrett-Lee P, Johnson L. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:16811692.

    • Search Google Scholar
    • Export Citation
  • 226.

    Martin M, Pienkowski T, Mackey J. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:23022313.

  • 227.

    Swain SM, Jeong JH, Geyer CE. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer [abstract]. Presented at the 2008 San Antonio Breast Cancer Symposium; December 10–14, 2008; San Antonio, Texas. Abstract 75.

    • Search Google Scholar
    • Export Citation
  • 228.

    Sparano JA, Wang M, Martino S. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node positive or high risk node negative breast cancer [abstract]. Presented at the 2005 San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.

    • Search Google Scholar
    • Export Citation
  • 229.

    Sparano JA, Wang M, Martino S. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:16631671.

  • 230.

    Jones S, Holmes FA, O'Shaughnessy J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:11771183.

    • Search Google Scholar
    • Export Citation
  • 231.

    Martin M, Rodriguez-Lescure A, Ruiz A. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805814.

    • Search Google Scholar
    • Export Citation
  • 232.

    Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:16521654.

  • 233.

    Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 512.

    • Search Google Scholar
    • Export Citation
  • 234.

    Perez EA, Suman VJ, Davidson NE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:12311238.

    • Search Google Scholar
    • Export Citation
  • 235.

    Tan-Chiu E, Yothers G, Romond E. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 236.

    Geyer CE Jr, Bryant JL, Romond EH. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 581.

    • Search Google Scholar
    • Export Citation
  • 237.

    Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:35253533.

    • Search Google Scholar
    • Export Citation
  • 238.

    Smith I, Procter M, Gelber RD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:2936.

    • Search Google Scholar
    • Export Citation
  • 239.

    Joensuu H, Bono P, Kataja V. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 2009;27:56855692.

    • Search Google Scholar
    • Export Citation
  • 240.

    Norris B, Chia S, Cheang M. Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors [abstract]. Presented at the 2006 San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 2031.

    • Search Google Scholar
    • Export Citation
  • 241.

    Gonzalez-Angulo AM, Litton JK, Broglio KR. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:57005706.

    • Search Google Scholar
    • Export Citation
  • 242.

    Curigliano G, Viale G, Bagnardi V. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:56935699.

    • Search Google Scholar
    • Export Citation
  • 243.

    Untch M, Gelber RD, Jackisch C. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:10901096.

    • Search Google Scholar
    • Export Citation
  • 244.

    Dang C, Fornier M, Sugarman S. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008;26:12161222.

    • Search Google Scholar
    • Export Citation
  • 245.

    Spielmann M, Roché H, Delozier T. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:61296134.

    • Search Google Scholar
    • Export Citation
  • 246.

    Aukema TS, Straver ME, Peeters MJ. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:32053210.

    • Search Google Scholar
    • Export Citation
  • 247.

    Fuster D, Duch J, Paredes P. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:47464751.

    • Search Google Scholar
    • Export Citation
  • 248.

    Groheux D, Moretti JL, Baillet G. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:695704.

    • Search Google Scholar
    • Export Citation
  • 249.

    van der Hoeven JJM, Krak NC, Hoekstra OS. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:12531259.

    • Search Google Scholar
    • Export Citation
  • 250.

    Alessio AM, Kinahan PE, Cheng PM. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 2004;42:10171032, vii.

  • 251.

    Wong TZ, Paulson EK, Nelson RC. Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol 2007;188:622629.

  • 252.

    Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:645660.

    • Search Google Scholar
    • Export Citation
  • 253.

    Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994;271:15871592.

    • Search Google Scholar
    • Export Citation
  • 254.

    Rosselli Del Turco M, Palli D, Cariddi A. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:15931597.

    • Search Google Scholar
    • Export Citation
  • 255.

    Smith TJ, Davidson NE, Schapira DV. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:10801082.

    • Search Google Scholar
    • Export Citation
  • 256.

    Bast RC, Ravdin P, Hayes DF. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:18651878.

    • Search Google Scholar
    • Export Citation
  • 257.

    Kirova YM, Stoppa-Lyonnet D, Savignoni A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:23042311.

    • Search Google Scholar
    • Export Citation
  • 258.

    Metcalfe K, Lynch HT, Ghadirian P. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:23282335.

  • 259.

    Pierce LJ, Levin AM, Rebbeck TR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:24372443.

    • Search Google Scholar
    • Export Citation
  • 260.

    ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006;107:14751478.

  • 261.

    Loprinzi CL, Kugler JW, Sloan JA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:20592063.

    • Search Google Scholar
    • Export Citation
  • 262.

    Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412413.

  • 263.

    Jin Y, Desta Z, Stearns V. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:3039.

    • Search Google Scholar
    • Export Citation
  • 264.

    Henry NL, Stearns V, Flockhart DA. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:12511255.

    • Search Google Scholar
    • Export Citation
  • 265.

    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487497.

  • 266.

    Li CI, Daling JR, Porter PL. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009;27:53125318.

    • Search Google Scholar
    • Export Citation
  • 267.

    Pierce JP, Stefanick ML, Flatt SW. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007;25:23452351.

    • Search Google Scholar
    • Export Citation
  • 268.

    Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009;15:323339.

    • Search Google Scholar
    • Export Citation
  • 269.

    Moran MS, Colasanto JM, Haffty BG. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J 2005;11:399403.

  • 270.

    Eubank WB, Mankoff D, Bhattacharya M. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479486.

    • Search Google Scholar
    • Export Citation
  • 271.

    Moon DH, Maddahi J, Silverman DH. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431435.

    • Search Google Scholar
    • Export Citation
  • 272.

    Katz A, Strom EA, Buchholz TA. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000;18:28172827.

    • Search Google Scholar
    • Export Citation
  • 273.

    van Tienhoven G, Voogd AC, Peterse JL. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999;35:3238.

    • Search Google Scholar
    • Export Citation
  • 274.

    Cox CE, Furman BT, Kiluk JV. Use of reoperative sentinel lymph node biopsy in breast cancer patients. J Am Coll Surg 2008;207:5761.

  • 275.

    Wapnir IL, Aebi S, Gelber S. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol 2008;15:32273231.

    • Search Google Scholar
    • Export Citation
  • 276.

    Jones EL, Oleson JR, Prosnitz LR. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:30793085.

  • 277.

    Vernon CC, Hand JW, Field SB. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731744.

    • Search Goo